Page last updated: 2024-08-25

9-aminocamptothecin and camptothecin

9-aminocamptothecin has been researched along with camptothecin in 124 studies

Research

Studies (124)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.81)	18.7374
1990's	73 (58.87)	18.2507
2000's	43 (34.68)	29.6817
2010's	7 (5.65)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boehm, JC; Caranfa, MJ; Faucette, LF; Gallagher, G; Hecht, SM; Holden, KG; Jakas, DR; Johnson, RK; Kingsbury, WD; McCabe, FL	1
Nicholas, AW; Wall, ME; Wani, MC	1
Burke, TG; Mi, Z	1
Besterman, JM; Leitner, P; Manikumar, G; Moore, L; Nicholas, AW; Tele, C; Truesdale, A; Wall, ME; Wani, MC	1
Chern, JW; Leu, YL; Roffler, SR	1
Aben, RW; Busscher, GF; de Groot, FM; Scheeren, HW	1
Ahluwalia, D; Bhupathi, D; Cai, X; Duan, JX; Hart, CP; Huang, H; Jiao, H; Jung, B; Jung, D; Liu, Q; Matteucci, J; Matteucci, M; Meng, F; Sun, JD	1
Burke, TG; Malak, H; Mi, Z	1
Giovanella, B; Harris, N; Mendoza, J; Pantazis, P	2
Sinha, BK	1
Daoud, SS; Fetouh, MI; Giovanella, BC	1
Allegra, CJ; Dahut, WL; Grem, JL; Klecker, RW; Strong, JM; Takimoto, CH; Yee, LK	1
Funk, LR; Hofmann, GA; Johnson, RK; Mattern, MR; McCabe, FL; Polsky, RM	1
Giovanella, BC; Harris, NJ; Hinz, HR; Natelson, EA	1
Kagel, JR; Riley, CM; Stella, VJ	1
Giovanella, BC	1
Malspeis, L; Supko, JG	1
Early, JA; Giovanella, BC; Hinz, HR; Kozielski, AJ; Mendoza, JT; Pantazis, P	1
Champoux, JJ; Ireton, GC; Madden, KR; Parker, LH; Stewart, L	1
Allegra, C; Arbuck, S; Chen, A; Corse, W; Dahut, W; Grem, J; Grollman, F; Hamilton, JM; Harold, N; Liang, M; Lieberman, R; Nakashima, H; Sorensen, M; Takimoto, C	1
Dancey, J; Eisenhauer, EA	1
Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D	1
Cheson, BD; Phillips, PH; Wilson, WH	1
Lehr, JE; Naik, H; Pienta, KJ	1
Boothman, DA; Kinsella, TJ; Lamond, JP; Wang, M	1
Hassan, R; Kohn, E; Sandor, V	1
Friedman, HS; Houghton, PJ	1
Arbuck, SG; Hochster, H; Liebes, L; Potmesil, M; Takimoto, CH	1
Bryant, M; Eder, JP; Grossbard, M; Huberman, M; Hurwitz, S; Kinchla, N; Kufe, DW; Lynch, T; Rodriguez, D; Rubin, E; Schnipper, L; Shapiro, C; Shulman, L; Stone, R; Supko, J; Toppmeyer, D; Vosburg, E; Xu, G	1
Willson, JK	1
Kirichenko, AV; Rich, TA; Travis, EL	1
Berry, B; Li, M; Moore, MJ; Thiessen, JJ	1
Allegra, CJ; Arbuck, SG; Cantilena, LR; Chen, AP; Dahut, W; Grem, JL; Hamilton, JM; Harold, N; Liang, MD; Lieberman, R; Nakashima, H; Takimoto, CH	1
Erickson-Miller, CL; May, RD; Murphy, MJ; Osborn, B; Page, JG; Parchment, RE; Tomaszewski, J	1
Kirichenko, AV; Newman, RA; Rich, TA; Travis, EL	1
Brumfield, A; Dookeran, KA; Rubin, JT	1
Allegra, CJ; Arbuck, SG; Band, RA; Cantilena, LR; Chen, AP; Dahut, W; Grem, JL; Hamilton, JM; Harold, N; Liang, MD; Lieberman, R; Marino, MT; Nakashima, H; Takimoto, CH	1
Loos, WJ; Nooter, K; Schellens, JH; Sparreboom, A; Stoter, G; Verweij, J	1
Abbruzzese, JL; Arbuck, SG; Ballard, WP; Bradof, JE; Diaz-Canton, E; Graham, S; Pazdur, R; Winn, R	1
Berkery, R; Harrison, J; Kelsen, DP; Kemeny, NE; Saltz, LB; Tong, W	1
Eisenhauer, EA; Feld, R; Firby, PS; Goldberg, RA; Manzo, J; Michael, M; Moore, MJ; Oza, AM; Siu, LL; Thiessen, JJ; Wainman, N	1
Bryant, M; Eder, JP; Kufe, DW; Lynch, T; Shulman, LN; Supko, JG; Vosburgh, E; Xu, G	1
Arbuck, SG; Kieffer, LV; Takimoto, CH	1
Fisher, JD; Grossman, S; Piantadosi, S	1
Balis, FM; Blaney, SM; Cole, DE; Godwin, K; Kuttesch, N; McCully, C; Murry, DJ; Takimoto, C	1
Fleming, GF; Iyer, L; Janisch, L; Mani, S; Ratain, MJ; Schilsky, RL; Wang, X	1
Dillahey, D; El-Galley, RE; Gomaa, A; Graham, SD; Keane, TE; McGuire, WP; Petros, JA; Sun, C	1
Chen, TL; Fisher, J; Gregory, R; Grochow, LB; Grossman, SA; Hochberg, F; Kim, L; Piantadosi, S	1
Cheson, BD; Elwood, P; Humphrey, R; Jaffe, ES; Kohler, DR; Little, R; Pearson, D; Steinberg, SM; Wilson, WH	1
Bernstein, M; Blaney, S; Casto, DT; Dubowy, R; Grier, H; Kretschmar, C; Langevin, AM; Pratt, C; Thomas, PJ; Vietti, T; Weitman, SD	1
Punt, CJ	1
de Jonge, MJ; Loos, WJ; Nooter, K; Porro, MG; Punt, CJ; Sparreboom, A; Verweij, J	1
Houghton, PJ; Stewart, CF; Thompson, J	1
Beavis, RC; Berman, Y; Devi, LA; Newcomb, EW; Reed, JC; Thomas, A; Wood, DE	1
Beijnen, JH; Bult, A; Herben, VM; Hillebrand, MJ; ten Bokkel Huinink, WW; van Gijn, R	1
Cooper, MR; de Souza, PL; Imondi, AR; Myers, CE	1
Dahut, W; Geoffroy, F; Grem, JL; Takimoto, CH	1
Bartel, S; Bharti, A; Hurwitz, S; Levy, S; Lynch, C; Rosowsky, A; Rubin, E; Toppmeyer, D; Trites, D; Wood, V	1
Goldwasser, F; Kohn, KW; Pommier, Y; Torres, R; Valenti, M	1
Ansari, RH; Fishkin, PA; Golomb, HM; Hoffman, PC; Klepsch, A; Krauss, S; Lad, TE; Masters, GA; Ratain, MJ; Sciortino, DF; Vokes, EE	1
Chuang, N; Cohen, HW; O'Leary, JJ; Potmesil, M; Ren, CJ; Shapiro, RL	1
Bigg, DC; Lavergne, O	1
Beran, M; Jeha, S; Kantarjian, H; O'Brien, S; Vitek, L	1
Dallaire, BK; de Jonge, MJ; Loos, WJ; Sparreboom, A; Verweij, J	1
Kirichenko, AV; Rich, TA	1
de Jonge, MJ; Loos, WJ; Nooter, K; Porro, MG; Punt, CJ; Sparreboom, A; Stoter, G; Verweij, J	1
Lad, TE; Minami, H; Nicholas, MK; Ratain, MJ; Vokes, EE	1
Arbuck, S; Beran, M; Bivins, C; Cheson, B; Cortes, J; Estey, E; Giles, F; Kantarjian, H; O'Brien, S; Tran, H; Vey, N	1
Barrows, LR; Li, XG; Pond, CD; Rubin, EH	1
Beijnen, JH; Herben, VM; Hillebrand, MJ; Lieverst, J; Porro, MG; Schellens, JH; Schoemaker, NE; Schot, M; ten Bokkel Huinink, WW; van Gijn, R	1
Dallaire, BK; de Jonge, MJ; Gelderblom, AH; Loos, WJ; Planting, AS; Punt, CJ; Sparreboom, A; van Beurden, V; van der Burg, ME; van Maanen, LW; Verweij, J; Wagener, DJ	1
Brouwer, E; Dallaire, BK; de Jonge, MJ; Gelderblom, HJ; Loos, WJ; Sparreboom, A; Verweij, J	1
Blanke, CD; Rothenberg, ML	1
Balcerzak, SP; Kraut, EH; Kuebler, JP; Mayernik, DG; O'Rourke, MA; Petrus, JJ; Young, D	1
Arbuck, SG; Kieffer, LV; Kieffer, ME; Takimoto, CH; Wright, J	1
Allegra, CJ; Grem, JL; Paull, K; Pommier, Y; Voeller, DM	1
Kirichenko, AV; Mason, K; Rich, TA; Straume, M; Teates, CD	1
de Bruijn, P; Loos, WJ; Sparreboom, A; Verweij, J	1
Arietta, R; Brockstein, B; Keubler, JP; Lad, T; Rosen, F; Sciortino, D; Vokes, E	1
Goldberg, RM; Hatfield, AK; Knost, JA; Krook, JE; Kugler, J; Mahoney, MR; Pitot, HC; Sargent, DJ	1
Downey, A; Hamilton, A; Hochster, H; Hornreich, G; Liebes, L; Muggia, F; Potmesil, M; Sorich, J; Wasserstrom, H	1
Beijnen, JH; Jonker, JW; Maliepaard, M; Scheffer, GL; Schellens, JH; Scheper, RJ; Schinkel, AH; Smit, JW	1
Takimoto, CH; Thomas, R	1
Firby, PS; Horn, L; Li, ML; Moore, MJ	1
Takimoto, CH	2
Fisher, JD; Glantz, M; Grossman, SA; Hochberg, F; Mikkelsen, T; Piantadosi, S	1
Kopecek, J; Kopecková, P; Lu, ZR; Sakuma, S	1
Burkey, B; Cmelak, A; Douglas, S; Murphy, BA; Netterville, J; Shyr, Y; Smith, W	1
Arbuck, S; Argiris, A; Cooper, DL; DiStasio, S; Foss, FM; Heald, P; Kuzel, T; Murren, JR	1
Arrieta, R; Golomb, HM; Gordon, GS; Hoffman, PC; Krauss, S; Mauer, AM; Rudin, CM; Vokes, EE; Watson, S	1
Allegra, CJ; Arbuck, SG; Band, RA; Chen, AP; Corse, W; Cottrell, J; Dahut, W; Grem, JL; Hamilton, JM; Harold, N; Liang, M; Llorens, V; Monahan, BP; Shapiro, JD; Smith, JA; Takimoto, CH; Thomas, RR; Wright, J	1
Berg, SL; Blaney, SM; Bomgaars, L	1
Beijnen, JH; Jansen, S; Rizzo, J; Rosing, H; Schellens, JH; Schoemaker, NE; Schöffski, P	1
Chiang, C; Hamilton, A; Hazarika, M; Hochster, H; Hornreich, G; Liebes, L; Muggia, FM; Newman, E; Potmesil, M; Sorich, J; Wadler, S	1
Bernt, KM; Li, ZY; Lieber, A; Ni, S; Roffler, SR; Steinwaerder, DS	1
Abbruzzese, JL; Madden, TL; Newman, RA; Tran, HT; Xiong, HQ	1
Bates, SE; Gounder, MK; Rajendra, R; Ross, DD; Rubin, EH; Saleem, A; Schellens, JH; Sinko, P	1
Dahut, W; Grem, JL; Ismail, AS; Leguizamo, J; Liang, MD; Pang, J; Quinn, M; Takimoto, CH	1
Hochster, H; Mandeli, J; Muggia, FM; Plimack, ER; Runowicz, CD; Sorich, J; Speyer, J; Wadler, S; Wallach, RC; Wright, J	1
Avadhani, A; Karrison, T; Kindler, HL; Mani, S; Vokes, EE; Wade-Oliver, K	1
Belani, CP; Egorin, MJ; Fakih, M; Jin, R; Jung, LL; Potter, DM; Ramanathan, RK; Strychor, S; Trump, DL; Walko, C; Zamboni, WC	1
Atsumi, R; Masubuchi, N; May, RD	1
Blessing, JA; Bloss, J; Miller, DS; Schilder, J; Schilder, R; Sorosky, J; Waggoner, S	1
Egorin, MJ; Eiseman, JL; Hamburger, DR; Jin, R; Joseph, E; Jung, LL; Ramanathan, RK; Strychor, S; Zamboni, WC	1
Ahluwalia, MS; Barnett, GH; Cohen, BH; Farray, D; Peereboom, DM; Snyder, J; Suh, JH	1
Egorin, MJ; Goel, S; Iqbal, T; Mani, S; Parise, RA; Repinski, TV; Strychor, S; Zamboni, WC	1
Gao, SQ; Kopeček, J; Kopečková, P; Lu, ZR; Petri, B	1
Davis, TA; Egorin, MJ; Jung, LL; King, CR; Mani, S; Marsh, S; Maruca, LJ; McLeod, HL; Parise, RA; Potter, DM; Ramanathan, RK; Strychor, S; Zamboni, WC	1
Barrows, LR; Marshall, KM; Pond, CD	1
O'Leary, J; Sewak, S; Sorich, J	1
Gao, SQ; Kopecek, J; Kopecková, P; Lu, ZR	1
Gao, SQ; Kopecek, J; Kopecková, P; Peterson, CM; Sun, Y	2
Herzog, TJ; Wethington, SL; Wright, JD	1
Bartlett, NL; Johnson, JL; Peterson, BA; Ratain, MJ; Wagner-Johnston, N	1
Chen, P; Huang, C; Li, K; Liu, M; Wang, L; Xue, J; Yan, Z; Zhu, Z	1
Patel, D; Rahman, S; Savva, M	2
Hamilton, G; Klameth, L; Rath, B; Thalhammer, T	1
Böhmdorfer, M; Hartl, A; Jaeger, W; Maier-Salamon, A; Reznicek, G; Thalhammer, T; Zupkó, I	1
Burnouf, PA; Chen, KC; Cheng, TL; Chou, HC; Huang, PT; Leu, YL; Prijovich, ZM; Roffler, SR	1

Reviews

18 review(s) available for 9-aminocamptothecin and camptothecin

Article	Year
Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs, 1995, Volume: 49, Issue:1 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Irinotecan; Neoplasms; Podophyllotoxin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	1995
Current perspectives on camptothecins in cancer treatment. British journal of cancer, 1996, Volume: 74, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1996
New anticancer agents in clinical development. Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:11 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; DNA Topoisomerases, Type I; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Paclitaxel; Prodrugs; Taxoids; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan	1995
Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors. International journal of radiation oncology, biology, physics, 1996, Sep-01, Volume: 36, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Cell Survival; DNA Topoisomerases, Type I; Dose-Response Relationship, Radiation; Humans; Melanoma; Radiation Tolerance; Time Factors; Topoisomerase I Inhibitors; Tumor Cells, Cultured	1996
9-Aminocamptothecin and beyond. Preclinical and clinical studies. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Forecasting; Humans	1996
Topoisomerase-I inhibitors in the management of colon cancer. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan	1996
DNA topoisomerase I inhibitors. Cancer chemotherapy and biological response modifiers, 1997, Volume: 17 Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
New drugs in the treatment of colorectal carcinoma. Cancer, 1998, Aug-15, Volume: 83, Issue:4 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil	1998
Animal models for studying the action of topoisomerase I targeted drugs. Biochimica et biophysica acta, 1998, Oct-01, Volume: 1400, Issue:1-3 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Division; Disease Models, Animal; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms, Experimental; Rodentia; Topoisomerase I Inhibitors; Transplantation, Heterologous	1998
[The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan]. Bulletin du cancer, 1998, Volume: Spec No Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Macromolecular Substances; Mice; Molecular Structure; Neoplasm Proteins; Prodrugs; Structure-Activity Relationship; Topoisomerase I Inhibitors	1998
Topoisomerase I inhibitors in the treatment of colorectal cancer. Seminars in oncology, 1999, Volume: 26, Issue:6 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan	1999
DNA topoisomerase I poisons. Cancer chemotherapy and biological response modifiers, 1999, Volume: 18 Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan	1999
Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography. Anti-cancer drugs, 2000, Volume: 11, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan	2000
Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Parenteral; Neoplasms; Ovarian Neoplasms; Topoisomerase I Inhibitors	2000
The clinical development of 9-aminocamptothecin. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Neoplasms	2000
Topoisomerase I inhibitors in the treatment of head and neck cancer. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:7 Suppl 8 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Irinotecan; Survival Analysis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2001
The development of camptothecin analogs in childhood cancers. The oncologist, 2001, Volume: 6, Issue:6 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Infant; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	2001
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert review of anticancer therapy, 2008, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	2008

Trials

41 trial(s) available for 9-aminocamptothecin and camptothecin

Article	Year
Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome	1996
Trials of 9-amino-20(S)-camptothecin in Boston. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Adult; Antineoplastic Agents; Boston; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Female; Humans; Leukemia; Male; Middle Aged; Neoplasms	1996
Clinical pharmacology of 9-aminocamptothecin. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Adult; Antineoplastic Agents; Camptothecin; Humans; Neoplasms; Topoisomerase I Inhibitors	1996
Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Half-Life; Humans; Male; Middle Aged; Neoplasms	1997
Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged	1997
9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. Cancer, 1997, Nov-01, Volume: 80, Issue:9 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Thrombocytopenia; Treatment Outcome	1997
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Colloids; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Regression Analysis; Salvage Therapy	1998
Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Colloids; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms	1998
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Female; Humans; Male; Middle Aged; Neoplasms	1998
Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:2 Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Camptothecin; Drug Administration Schedule; Drug Interactions; Glioblastoma; Humans; Middle Aged	1998
Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lymphoma; Male; Maximum Allowable Concentration; Middle Aged; Recurrence	1998
Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:7 Topics: Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Male; Maximum Allowable Concentration; Neoplasms; Treatment Outcome; United States	1998
Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:8 Topics: Administration, Oral; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Capsules; Drug Administration Schedule; Humans; Injections, Intravenous; Intestinal Absorption; Middle Aged; Neoplasms	1998
Effects of 9-aminocamptothecin on newly synthesized DNA in patient bone marrow samples. Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Camptothecin; DNA; Half-Life; Humans; Hydrogen-Ion Concentration; Middle Aged	1995
A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia	1995
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:10 Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome	1998
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva. Clinical pharmacology and therapeutics, 1999, Volume: 65, Issue:5 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Saliva	1999
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:6 Topics: Adult; Aged; Anticonvulsants; Blood Cell Count; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Glioma; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Logistic Models; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged	1999
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colloids; Humans; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma	1999
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Colloids; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Female; Hematopoiesis; Humans; Infusions, Intravenous; Lactones; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia	1999
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Least-Squares Analysis; Likelihood Functions; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacokinetics; Thrombocytopenia	1999
Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans. Anti-cancer drugs, 1999, Volume: 10, Issue:8 Topics: Animals; Antineoplastic Agents; Biological Availability; Blood Proteins; Camptothecin; Chlorocebus aethiops; Drug Stability; Enzyme Inhibitors; Erythrocytes; Humans; Hydrogen-Ion Concentration; Hydrolysis; Mice; Time Factors; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Vero Cells	1999
A phase II study of 9-aminocamptothecin in patients with refractory breast cancer. Cancer investigation, 2000, Volume: 18, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Infusions, Intravenous; Middle Aged; Treatment Outcome	2000
Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer. Investigational new drugs, 2000, Volume: 18, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged	2000
A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. Cancer, 2000, Oct-15, Volume: 89, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Time Factors	2000
Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma. Investigational new drugs, 2001, Volume: 19, Issue:4 Topics: Adult; Antineoplastic Agents; Camptothecin; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neutropenia; Skin Neoplasms; Time Factors; Treatment Outcome	2001
A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. Investigational new drugs, 2001, Volume: 19, Issue:4 Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome	2001
A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients. Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hematologic Tests; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Platelet Count	2001
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days. Anti-cancer drugs, 2002, Volume: 13, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms	2002
Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms	2003
A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:4 Topics: Acetamides; Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Cell Count; Camptothecin; Colloids; Drug Resistance, Neoplasm; Excipients; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms	2003
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome	2004
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Investigational new drugs, 2004, Volume: 22, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Stomach Neoplasms; Survival Rate; Treatment Outcome	2004
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:6 Topics: Administration, Oral; Camptothecin; Drug Administration Schedule; Humans; Neoplasms	2004
Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Gynecologic oncology, 2005, Volume: 96, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms	2005
Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme. Investigational new drugs, 2006, Volume: 24, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Treatment Outcome	2006
Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Camptothecin; Cross-Over Studies; Fasting; Female; Food; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms	2006
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Investigational new drugs, 2006, Volume: 24, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP-Binding Cassette Transporters; Camptothecin; Female; Genotype; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasms; Polymorphism, Single Nucleotide	2006
Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen. Anti-cancer drugs, 2006, Volume: 17, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Time Factors	2006
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate	2009
A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4 Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Time Factors	2011

Other Studies

65 other study(ies) available for 9-aminocamptothecin and camptothecin

Article	Year
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. Journal of medicinal chemistry, 1991, Volume: 34, Issue:1 Topics: Animals; Antineoplastic Agents; Camptothecin; Cattle; Cell Line; Colonic Neoplasms; DNA, Superhelical; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Indicators and Reagents; Leukemia L1210; Lung Neoplasms; Melanoma, Experimental; Mice; Molecular Structure; Plasmids; Structure-Activity Relationship; Thymus Gland; Topoisomerase I Inhibitors; Transplantation, Heterologous	1991
Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues. Journal of medicinal chemistry, 1986, Volume: 29, Issue:11 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Leukemia L1210; Solubility; Structure-Activity Relationship	1986
The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. Journal of medicinal chemistry, 1994, Jan-07, Volume: 37, Issue:1 Topics: Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Half-Life; Irinotecan; Kinetics; Lactones; Molecular Structure; Serum Albumin; Spectrometry, Fluorescence; Structure-Activity Relationship; Topotecan	1994
Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. Journal of medicinal chemistry, 1993, Sep-03, Volume: 36, Issue:18 Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Humans; Leukemia L1210; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred DBA; Molecular Conformation; Molecular Structure; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured	1993
Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). Journal of medicinal chemistry, 1999, Sep-09, Volume: 42, Issue:18 Topics: Antibodies; Antineoplastic Agents; Camptothecin; Drug Design; Glucuronates; Glucuronidase; Humans; Hydrogen-Ion Concentration; Immunotherapy; Prodrugs; Solubility; Tumor Cells, Cultured	1999
Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin. Bioorganic & medicinal chemistry letters, 2002, Sep-02, Volume: 12, Issue:17 Topics: Camptothecin; Cell Death; Drug Design; Fibrinolysin; Humans; Neoplasm Proteins; Oligopeptides; Prodrugs; Tumor Cells, Cultured	2002
14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment. Journal of medicinal chemistry, 2011, Mar-24, Volume: 54, Issue:6 Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bone Marrow Cells; Brain; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Species Specificity; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous	2011
Clinical trials referral resource. Clinical trials with 9-aminocamptothecin. Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:8 Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colonic Neoplasms; Humans; Lung Neoplasms; Lymphoma; Neutropenia	1995
Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry, 1995, Oct-24, Volume: 34, Issue:42 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; DNA, Neoplasm; Drug Stability; Electrophoresis, Agar Gel; Flow Cytometry; Fluorescence Polarization; HL-60 Cells; Humans; Irinotecan; Lactones; Molecular Structure; Serum Albumin; Topoisomerase I Inhibitors; Topotecan	1995
The role of pH and serum albumin in the metabolic conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human hematopoietic and other cells. European journal of haematology, 1995, Volume: 55, Issue:3 Topics: Antineoplastic Agents; Camptothecin; Hematopoietic Stem Cells; Humans; Hydrogen-Ion Concentration; Serum Albumin; Tumor Cells, Cultured	1995
Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts. Anti-cancer drugs, 1995, Volume: 6, Issue:1 Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Breast Neoplasms; Camptothecin; Carcinoma; Cholesterol; Drug Carriers; Drug Evaluation, Preclinical; Humans; Liposomes; Melanoma, Experimental; Mice; Mice, Nude; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Phosphatidylinositols; Remission Induction; Skin Neoplasms; Sphingomyelins; Topoisomerase I Inhibitors	1995
Conversion of 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro. European journal of haematology, 1994, Volume: 53, Issue:4 Topics: Animals; Antineoplastic Agents; Blood Cells; Camptothecin; Cells, Cultured; Humans; Mice; Tumor Cells, Cultured	1994
Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. Journal of chromatography. B, Biomedical applications, 1994, Apr-22, Volume: 655, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Humans; Hydrolysis; Indicators and Reagents; Spectrometry, Fluorescence	1994
In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncology research, 1993, Volume: 5, Issue:12 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; CHO Cells; Cricetinae; DNA Damage; Drug Resistance; Female; Irinotecan; Leukemia P388; Mice; Topotecan	1993
Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. Cancer research, 1994, Jun-15, Volume: 54, Issue:12 Topics: Administration, Oral; Animals; Camptothecin; Dogs; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Mice; Mice, Nude; Species Specificity; Tissue Distribution	1994
A liquid chromatographic method for the determination of the enantiomeric purity of the anticancer drug, 9-amino-20(S)-camptothecin. Journal of pharmaceutical and biomedical analysis, 1993, Volume: 11, Issue:9 Topics: Antineoplastic Agents; Camptothecin; Chromatography, Liquid; Stereoisomerism	1993
New perspectives in colon cancer chemotherapy. Diseases of the colon and rectum, 1994, Volume: 37, Issue:2 Suppl Topics: Animals; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasm Transplantation	1994
Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer research, 1993, Jul-01, Volume: 53, Issue:13 Topics: Animals; Camptothecin; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Structure-Activity Relationship; Tissue Distribution	1993
Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. International journal of cancer, 1993, Mar-12, Volume: 53, Issue:5 Topics: Animals; Camptothecin; Cell Cycle; Cell Division; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured	1993
Biochemical and biophysical analyses of recombinant forms of human topoisomerase I. The Journal of biological chemistry, 1996, Mar-29, Volume: 271, Issue:13 Topics: Adenosine Triphosphate; Amino Acid Sequence; Base Sequence; Camptothecin; Cations, Divalent; Circular Dichroism; Conserved Sequence; DNA Topoisomerases, Type I; Humans; Kinetics; Magnesium; Molecular Sequence Data; Oligodeoxyribonucleotides; Potassium Chloride; Protein Conformation; Protein Folding; Protein Structure, Secondary; Recombinant Proteins; Topoisomerase I Inhibitors; Topotecan	1996
Clinical trials at the medicine branch of the NCI-part 2. Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Clinical Trials as Topic; Eye Neoplasms; Humans; Immunotherapy; Lymphoma; Lymphoma, Non-Hodgkin; Recurrence	1995
Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine. Urology, 1996, Volume: 48, Issue:3 Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Estramustine; Humans; Male; Prostatic Neoplasms; Rats	1996
Exacerbation of pseudogout by granulocyte colony-stimulating factor. Annals of internal medicine, 1996, Nov-01, Volume: 125, Issue:9 Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Chondrocalcinosis; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Humans; Ovarian Neoplasms; Recombinant Proteins; Recurrence	1996
Treatment of central nervous system xenografts with camptothecins. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Topotecan; Transplantation, Heterologous	1996
Radiation enhancement by 9-aminocamptothecin. Evidence for improved therapeutic ratio with a multiple dose schedule. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Animals; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H	1996
Pharmacokinetic and pharmacodynamic studies of 9-aminocamptothecin in vitro against human cancer cells. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Antineoplastic Agents; Camptothecin; Drug Screening Assays, Antitumor; Humans; Tumor Cells, Cultured	1996
Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer chemotherapy and pharmacology, 1997, Volume: 39, Issue:5 Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Camptothecin; Cells, Cultured; Colony-Forming Units Assay; Dogs; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Interleukin-3; Mice; Recombinant Proteins; Topoisomerase II Inhibitors; Topotecan	1997
Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin. Cancer research, 1997, May-15, Volume: 57, Issue:10 Topics: Animals; Antineoplastic Agents; Camptothecin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Radiation-Sensitizing Agents	1997
A comparison of locoregional depot and systemic preparations of 9-aminocamptothecin for treatment of liver metastases in a rat tumor model: superior antitumor activity of sustained-release preparation. Annals of surgical oncology, 1997, Volume: 4, Issue:4 Topics: Animals; Antineoplastic Agents; Camptothecin; Delayed-Action Preparations; Disease Models, Animal; Drug Delivery Systems; Ethiodized Oil; Liver Neoplasms, Experimental; Rats; Rats, Inbred F344	1997
Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection. Journal of chromatography. B, Biomedical sciences and applications, 1997, Jul-04, Volume: 694, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Lactones; Neoplasms; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence	1997
Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:6 Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Glioblastoma; Humans; Models, Theoretical; Neoplasm Recurrence, Local; Reproducibility of Results	1998
Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:6 Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Irinotecan; Macaca mulatta; Male; Nausea; Vomiting	1998
Camptothecin analogues/cisplatin: an effective treatment of advanced bladder cancer in a preclinical in vivo model system. The Journal of urology, 1998, Volume: 160, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Staging; Tumor Cells, Cultured; Urinary Bladder Neoplasms	1998
Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene, 1998, Sep-03, Volume: 17, Issue:9 Topics: Alanine; Amino Acid Sequence; Apoptosis; Aspartic Acid; bcl-2-Associated X Protein; Binding Sites; Calpain; Camptothecin; Cell Death; Cell Extracts; Cell Membrane; Cysteine Proteinase Inhibitors; Dipeptides; HL-60 Cells; Humans; Hydrolysis; Leucine; Molecular Sequence Data; Mutation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Substrate Specificity	1998
High-performance liquid chromatographic analysis of the investigational anticancer drug 9-aminocamptothecin, as the lactone form and as the total of the lactone and the hydroxycarboxylate forms, in micro-volumes of human plasma. Journal of pharmaceutical and biomedical analysis, 1998, Volume: 17, Issue:8 Topics: Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug Stability; Humans; Lactones; Reproducibility of Results	1998
9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:2 Topics: Animals; Antineoplastic Agents; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lactones; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prostatic Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured	1997
Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:4 Topics: Antineoplastic Agents; Aphidicolin; Camptothecin; Cisplatin; DNA; DNA Damage; DNA, Single-Stranded; Drug Synergism; Female; Humans; S Phase; Tumor Cells, Cultured	1996
Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cornea; Disease Models, Animal; Fibroblast Growth Factor 2; Irinotecan; Mice; Mice, Inbred Strains; Neovascularization, Pathologic; Neovascularization, Physiologic; Topotecan; Vincristine	1999
Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia. Leukemia & lymphoma, 1998, Volume: 32, Issue:1-2 Topics: Acute Disease; Administration, Oral; Animals; Camptothecin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; HLA-DQ alpha-Chains; HLA-DQ Antigens; Humans; Injections, Intravenous; Leukemia, Experimental; Leukemia, Myeloid; Mice; Mice, SCID; Neoplasm Transplantation; Survival Rate	1998
Radiation enhancement by 9-aminocamptothecin: the effect of fractionation and timing of administration. International journal of radiation oncology, biology, physics, 1999, Jun-01, Volume: 44, Issue:3 Topics: Animals; Antineoplastic Agents; Camptothecin; Circadian Rhythm; Combined Modality Therapy; Drug Administration Schedule; Female; Injections, Intramuscular; Mammary Neoplasms, Animal; Mice; Mice, Inbred C3H; Radiation-Sensitizing Agents; Specific Pathogen-Free Organisms	1999
Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis. Drug metabolism and disposition: the biological fate of chemicals, 1999, Volume: 27, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Male; Middle Aged	1999
Effects of mutations in the F361 to R364 region of topoisomerase I (Topo I), in the presence and absence of 9-aminocamptothecin, on the Topo I-DNA interaction. Anti-cancer drugs, 1999, Volume: 10, Issue:7 Topics: Antineoplastic Agents; Camptothecin; Catalysis; DNA; DNA Topoisomerases, Type I; Mutation; Structure-Activity Relationship	1999
Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs. Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Phosphorylation; Thymidine Kinase; Thymidylate Synthase; Time Factors; Topotecan; Tumor Cells, Cultured; Zidovudine	2000
Nuclear scintigraphic assessment of intestinal dysfunction after combined treatment with 9-amino-20(S)-camptothecin (9-AC) and irradiation. International journal of radiation oncology, biology, physics, 2000, Jul-01, Volume: 47, Issue:4 Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Intestinal Absorption; Jejunum; Mice; Mice, Inbred C3H; Radiation Dosage; Radiobiology; Radiopharmaceuticals; Sodium Pertechnetate Tc 99m; Whole-Body Irradiation	2000
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	2000
Pharmacological determinants of 9-aminocamptothecin cytotoxicity. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:1 Topics: Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Humans; Tumor Cells, Cultured; Urinary Bladder Neoplasms	2001
Why drugs fail: of mice and men revisited. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:2 Topics: Animals; Antineoplastic Agents; Biological Availability; Camptothecin; Enzyme Inhibitors; Humans; Mice; Neoplasms; Tissue Distribution; Topoisomerase I Inhibitors	2001
Lack of efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high-grade astrocytoma. NABTT CNS Consortium. Neuro-oncology, 2000, Volume: 2, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Treatment Failure	2000
Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin. Journal of controlled release : official journal of the Controlled Release Society, 2001, Aug-10, Volume: 75, Issue:3 Topics: Animals; Antineoplastic Agents; Camptothecin; Colon; Male; Methacrylates; Rats; Rats, Sprague-Dawley	2001
Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Aug-05, Volume: 775, Issue:2 Topics: Camptothecin; Chromatography, High Pressure Liquid; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet	2002
Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors. Cancer research, 2002, Nov-01, Volume: 62, Issue:21 Topics: Adenoviridae; Biotransformation; Camptothecin; Cell Cycle; Combined Modality Therapy; Cytopathogenic Effect, Viral; Cytosine Deaminase; DNA Replication; Flucytosine; Fluorouracil; Genetic Therapy; Glucuronidase; Glucuronides; HeLa Cells; Humans; Nucleoside Deaminases; Pentosyltransferases; Prodrugs; Transgenes; Virus Replication	2002
Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer research, 2003, Jun-15, Volume: 63, Issue:12 Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Division; Dogs; Drug Resistance, Neoplasm; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Recombinant Fusion Proteins; Selection, Genetic; Transfection; Tumor Cells, Cultured	2003
A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-01, Volume: 10, Issue:19 Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Camptothecin; Colony-Forming Units Assay; Dogs; Granulocyte Precursor Cells; Granulocytes; Humans; Inhibitory Concentration 50; Irinotecan; Macrophages; Maximum Tolerated Dose; Mice; Models, Biological	2004
Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jul-01, Volume: 11, Issue:13 Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; HT29 Cells; Humans; Mice; Mice, SCID; Treatment Outcome; Xenograft Model Antitumor Assays	2005
Are there any better camptothecins than the ones we have? Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Humans; Irinotecan; Pancreatic Neoplasms; Research; Topoisomerase I Inhibitors	2003
Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. Journal of controlled release : official journal of the Controlled Release Society, 2006, Jan-10, Volume: 110, Issue:2 Topics: Animals; Buffers; Camptothecin; Chromatography, High Pressure Liquid; Colon; Drug Delivery Systems; Indicators and Reagents; Intestinal Mucosa; Intestine, Large; Intestine, Small; Male; Methacrylates; Rats; Rats, Sprague-Dawley; Spectrometry, Fluorescence	2006
Identification of a small topoisomerase I-binding peptide that has synergistic antitumor activity with 9-aminocamptothecin. Molecular cancer therapeutics, 2006, Volume: 5, Issue:3 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Synergism; Humans; Mice; Mice, Nude; Molecular Sequence Data; Neoplasms; Oligonucleotides; Peptide Library; Peptides; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays	2006
Biodistribution and pharmacokinetics of colon-specific HPMA copolymer--9-aminocamptothecin conjugate in mice. Journal of controlled release : official journal of the Controlled Release Society, 2007, Feb-12, Volume: 117, Issue:2 Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Cecum; Colon; Drug Delivery Systems; Feces; Female; Injections, Intravenous; Intestine, Small; Methacrylates; Mice; Molecular Structure; Polymers; Tissue Distribution	2007
Pharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released from colon-specific HPMA copolymer-9-AC conjugate in rats. Pharmaceutical research, 2008, Volume: 25, Issue:1 Topics: Algorithms; Anesthetics, Local; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cecum; Colon; Drug Delivery Systems; Gastrointestinal Transit; Indicators and Reagents; Injections, Intravenous; Intestinal Absorption; Lidocaine; Liver; Male; Methacrylates; Models, Statistical; Protein Binding; Rats; Rats, Wistar	2008
Antitumor efficacy of colon-specific HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenografts. Macromolecular bioscience, 2009, Nov-10, Volume: 9, Issue:11 Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Carriers; Drug Delivery Systems; Female; Humans; Male; Materials Testing; Methacrylates; Mice; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Polymers; Survival Rate; Transplantation, Heterologous; Xenograft Model Antitumor Assays	2009
Kinetic and thermodynamic studies of 9-aminocamptothecin hydrolysis at physiological pH in the presence of human serum albumin. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2013, Aug-16, Volume: 49, Issue:5 Topics: Camptothecin; Carboxylic Acids; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Lactones; Protein Binding; Serum Albumin; Thermodynamics	2013
Physicochemical characterization of 9-aminocamptothecin in aqueous solutions. AAPS PharmSciTech, 2014, Volume: 15, Issue:1 Topics: Camptothecin; Chemistry, Pharmaceutical; Hydrogen-Ion Concentration; Hydrolysis; Solubility; Solutions; Temperature; Thermodynamics	2014
Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines. Molecules (Basel, Switzerland), 2014, Feb-17, Volume: 19, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Small Cell Lung Carcinoma; Topotecan	2014
Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy. International journal of oncology, 2014, Volume: 45, Issue:2 Topics: Aged; Animals; Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP3A; Female; Humans; Male; Microsomes, Liver; Middle Aged; Rats; Rats, Wistar; Species Specificity; Topoisomerase I Inhibitors	2014
Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation. Molecular pharmaceutics, 2016, Apr-04, Volume: 13, Issue:4 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Glucuronidase; Glucuronides; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Prodrugs; Topotecan	2016